ICU sedation, delirium & recovery
Effects of Subanesthetic Oromucosal Dexmedetomidine on Sleep in Humans: A Randomized, Controlled Pharmacokinetics–Pharmacodynamics Study
Authors' conclusion
The favorable pharmacokinetic and pharmacodynamic profile of oromucosal dexmedetomidine delivery warrants further dose-finding and clinical studies to establish the exact roles of α 2 receptor agonism in pharmacologic sleep enhancement and as a possible novel mechanism to alleviate stress-related insomnia.
Study context
- Population
- Good sleepers (pilot, sublingual) and poor sleepers (main, buccal)pilot n = 8
- Comparison
- Oromucosal dexmedetomidine 20 and 40 µg vs placebo
Methodological detailsdouble-blind, placebo-controlled, pilot study and main study
- Double-blind
- Placebo-controlled
- Pilot study and main study
Primary result
As reported in the abstract
Pharmacokinetics and sleep (polysomnography) in poor sleepers, buccal formulation
- 40 µg shortened sleep latency (min)
- 11.5
- 40 µg increased time in non-rapid eye movement sleep (min)
- 37.2
- 40 µg elevated non-rapid eye movement sleep EEG slow-wave energy (0.75 to 4.0 Hz), first half of night, by roughly
- 23%
- Rapid eye movement sleep latency dose-dependently prolonged, 20 µg (min)
- 55.0
- Rapid eye movement sleep latency dose-dependently prolonged, 40 µg (min)
- 115.3
Further findings
Nocturnal cortisol, melatonin, heart rate; morning cortisol
- Not significantly affected by dexmedetomidine
Safety
Postawakening orthostatic regulation, subjective sleepiness and mood, psychomotor vigilance
- Did not differ among the conditions
Original publication
Effects of Subanesthetic Oromucosal Dexmedetomidine on Sleep in Humans: A Randomized, Controlled Pharmacokinetics–Pharmacodynamics Study. Anesthesiology. Published 27 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →